Tribal Patent Pacts An 'Assault' On IPR System, Fed. Circ. Told
Several generic drug companies have urged the Federal Circuit to uphold the Patent Trial and Appeal Board's finding that it could reevaluate patents for the dry-eye drug Restasis, in spite of...To view the full article, register now.
Already a subscriber? Click here to view full article